It needs to be explored howlethal graft-versus-host effects by T cells from such donors can be circumvented.However, the success of strategies as allogeneic Epstein-Barr virus (EBV) nuclearantigen (EBNA)-specific T cells sharing major MHC allele with the patient, that cantreat successfully post-transplant lymphoproliferative disease (32) and even bulky EBV-positive lymphomas (33, 34),sets grounds for hope. Here, HLA-C is linked to lymphoma.